The Influence of Tongxinluo Capsule and Atorvastatin on In-stent Restenosis and Inflammatory Factors after Percutaneous Coronary Intervention
Liu Lei
Jiang Tao
Abstract：Objective To investigate the effect of Tongxinluo capsule(TXLC) combined with atorvastatin on in-stent restenosis (ISR) and inflammatory factors after percutaneous coronary intervention (PCI).Methods One hundred and fifty-six patients after PCI was chosen as the research objects and randomly divided into control group treated with aspirin and clopidogrel,group A treated with aspirin,clopidogrel and atorvastatin,group B treated with aspirin,clopidogrel,atorvastatin,TXLC for 6 months with monthly follow-ups.The recurrence of major adverse cardiovascular events (MACE) were recorded.The incidence of ISR and MACE,the levels of serum high-sensitivity C-reactive protein(hs-CRP),interleukin(IL)-6,and tumor necrosis factor(TNF)-α were observed before and after treatment.Results After 6 months of treatment,the incidence of ISR and MACE,the levels of serum hs-CRP,IL-6,and TNF-α in group A and group B were were significantly lower than those in control group (P＜0.05),which was lower in group B than those in group A (P＜0.05).Conclusion On the basis of routine antiplatelet therapy,TXLC and atorvastatin can significantly reduce the incidence of ISR and MACE and the inflammatory factors levels.
Keywords：Tongxinluo capsuleatorvastatinpercutaneous coronary interventionin-stent restenosisinflammatory factors
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 769-771 )